Therapeutic monitoring of benzodiazepines in the management of pain: Current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safety

Clinica Chimica Acta

Volumn 413, Issue 15-16, 2012, Pages 1199-1202

  Mikel, Charles ^a   Pesce, Amadeo J ^a   Rosenthal, Murray ^a   West, Cameron ^a  

^a Millennium Laboratories   (United States)

Author keywords

Benzodiazepines; LC MS MS; Opiates; Point of care testing

Indexed keywords

ALPHA HYDROXYALPRAZOLAM; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; FLURAZEPAM; LORAZEPAM; NORDAZEPAM; OXAZEPAM; TEMAZEPAM; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG MONITORING; DRUG SAFETY; DRUG USE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PAIN; PATIENT MONITORING; PATIENT SAFETY; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS; VALIDATION PROCESS;

BENZODIAZEPINES; CHROMATOGRAPHY, LIQUID; CLONAZEPAM; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOASSAY; LORAZEPAM; MASS SPECTROMETRY; PAIN MEASUREMENT; PATIENT SAFETY; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY;

EID: 84861331690     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.03.017     Document Type: Article

References (24)

1. Drug Abuse Warning Network, S62.2007 National estimates of drug-related emergency department visits 2010, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD, .
2. Pesce A. Millennium Research Institute. Unpublished data from 290,627 de-identified specimens tested by LC-MS/MS at Millennium Laboratories, Inc. between November 2009 and September 2010.
3. Chou R., Fanciullo G.J., Fine P.G., et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10(2):113-130.
4. Drug tests by type: cups Accessed: January 4, 2012. DrugTestCentral.com. http://www.drugtestcentral.com/Cups-C2.aspx?gclid=CJT65e7dqq0CFasaQgodhmhtmA.
5. Fraser A.D. Psychotropic agents: the benzodiazepines. The clinical toxicology laboratory: contemporary practice of poisoning evaluation 2001, 211-221. American Association for Clinical Chemistry, Inc., Washington, DC. L.C. Shaw, T.C. Kwong, T.G. Rosano, P.J. Orsolak, B.A. Wolf, B. Magnani (Eds.).
6. Beck O., Lafolie P., Hjemdahl P., Borg S., Odelius G., Wirbing P. Detection of benzodiazepine intake in therapeutic doses by immunoanalysis of urine: Two techniques evaluated and modified for improved performance. Clin Chem 1992, 38(2):271-275.
7. Meatherall R. Optimal enzymatic hydrolysis of urinary benzodiazepine conjugates. J Anal Toxicol 1994, 18(7):382-384.
8. Fraser A.D., Meatherall R. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values. J Anal Toxicol 1996, 20(4):217-223.
9. Meatherall R., Fraser A.D. Comparison of four immunoassays for the detection of lorazepam in urine. Ther Drug Monit 1998, 20(6):673-675.
10. White R.M., Black M.L. Pain management testing reference 2008, AACC Press, Washington.
11. West R., Pesce A., West C., et al. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population. Pain Physician 2010, 13(1):71-78.
12. Brahm N.C., Yeager L.L., Fox M.D., Farmer K.C., Palmer T.A. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm 2010, 67(16):1344-1350.
13. Manchikanti L., Malla Y., Wargo B.W., et al. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS). Pain Physician 2010, 13(1):E1-E22.
14. Manchikanti L., Malla Y., Wargo B.W., Fellows B. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing. Pain Physician 2011, 14(3):259-270.
15. Mikel C., Almazan P., West R., et al. LC-MS/MS extends the range of drug analysis in pain patients. Ther Drug Monit 2009, 31(6):746-748.
16. Pesce A., Rosenthal M., West R., et al. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician 2010, 13(3):273-281.
17. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Radiology 2003, 226(1):24-28.
18. Horn P.S. Ch. 24 reference intervals and clinical decision limits. Clinical chemistry: theory, analysis, and correlation 2010, 449-451. Elsevier, St. Louis. L.A. Kaplan, A.J. Pesce (Eds.).
19. Reisfield G.M., Salazar E., Bertholf R.L. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci 2007, 37(4):301-314.
20. Greene D.N., Lehman C.M., McMillin G.A. Evaluation of the integrated E-Z split key(®) cup II for rapid detection of twelve drug classes in urine. J Anal Toxicol 2011, 35(1):46-53.
21. Nichols J.H., Christenson R.H., Clarke W., et al. Executive summary. The National Academy of Clinical Biochemistry laboratory medicine practice guideline: evidence-based practice for point-of-care testing. Clin Chim Acta 2007, 379(1-2):14-28.
22. Pesce A., Rosenthal M., Gonzales E., West R., Mikel C., West C., Latyshev S., Almazan P. Non-prescription medication taking behaviors in patients prescribed morphine, hydrocodone, and oxycodone. J Opioid Manag 2012, In Review.
23. Crews B., Latyshev S., Mikel C., et al. Improved detection of ethyl glucuronide and ethyl sulfate in a pain management population using high-throughput LC-MS/MS. J Opioid Manag 2010, 6(6):415-421.
24. Laffer A., Murphy R., Wingarden W., et al. An economic analysis of the costs and benefits associated with regular urine drug testing for chronic pain patients in the United States October 2011, Laffer Associates and Millennium Research Institute, Washington D.C.